MA27604A1 - Sels fumarates cristallins de furo [2,3-c] pyridinylcarboxamide a substituant 1- azabicyclo [2.2.2] octyle, compositions les contenant, et leur preparation - Google Patents

Sels fumarates cristallins de furo [2,3-c] pyridinylcarboxamide a substituant 1- azabicyclo [2.2.2] octyle, compositions les contenant, et leur preparation

Info

Publication number
MA27604A1
MA27604A1 MA28315A MA28315A MA27604A1 MA 27604 A1 MA27604 A1 MA 27604A1 MA 28315 A MA28315 A MA 28315A MA 28315 A MA28315 A MA 28315A MA 27604 A1 MA27604 A1 MA 27604A1
Authority
MA
Morocco
Prior art keywords
furo
azabicyclo
preparation
compositions containing
salts
Prior art date
Application number
MA28315A
Other languages
English (en)
Inventor
Jon Gordon Selbo
Bradley Dee Hewitt
David Warner Rappath
Donn Gregory Wishka
Ahmad Yahya Sheikh
Original Assignee
Pharmacia & Upjohn Co Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia & Upjohn Co Llc filed Critical Pharmacia & Upjohn Co Llc
Publication of MA27604A1 publication Critical patent/MA27604A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • C07D453/04—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems having a quinolyl-4, a substituted quinolyl-4 or a alkylenedioxy-quinolyl-4 radical linked through only one carbon atom, attached in position 2, e.g. quinine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Addiction (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Sels fumarates cristallins de furo[2,3-c]pyri-dinylcarboxamide à substituant 1-azabicyclo[2.2.2]octyle, compositions les contenant, et leur préparation La présente invention propose des sels consistant en fumarates de N-[1-azabicyclo[2.2.2]oct-3-yl]furo[2,3-c]pyridine-5-carboxamide, des compositions les contenant, leurs mélanges racémiques ou leurs énantiomères purs, et leur préparation. Les sels consistant en fumarates sont utiles pour traiter des maladies ou affections dans lesquelles on sait qu'(alpha)7nAChR est impliqué. Formule (I).
MA28315A 2002-12-06 2005-06-06 Sels fumarates cristallins de furo [2,3-c] pyridinylcarboxamide a substituant 1- azabicyclo [2.2.2] octyle, compositions les contenant, et leur preparation MA27604A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US43161902P 2002-12-06 2002-12-06

Publications (1)

Publication Number Publication Date
MA27604A1 true MA27604A1 (fr) 2005-11-01

Family

ID=32507764

Family Applications (1)

Application Number Title Priority Date Filing Date
MA28315A MA27604A1 (fr) 2002-12-06 2005-06-06 Sels fumarates cristallins de furo [2,3-c] pyridinylcarboxamide a substituant 1- azabicyclo [2.2.2] octyle, compositions les contenant, et leur preparation

Country Status (22)

Country Link
US (1) US20050165047A1 (fr)
EP (1) EP1572700A1 (fr)
JP (1) JP2006510664A (fr)
KR (1) KR20050087826A (fr)
CN (1) CN1720248A (fr)
AR (1) AR042295A1 (fr)
AU (1) AU2003302911A1 (fr)
BR (1) BR0317019A (fr)
CA (1) CA2506529A1 (fr)
CR (1) CR7859A (fr)
EA (1) EA200500738A1 (fr)
EC (1) ECSP055834A (fr)
HR (1) HRP20050494A2 (fr)
IS (1) IS7844A (fr)
MA (1) MA27604A1 (fr)
MX (1) MXPA05005943A (fr)
NO (1) NO20052560L (fr)
OA (1) OA12968A (fr)
PL (1) PL377052A1 (fr)
TW (1) TW200427691A (fr)
WO (1) WO2004052894A1 (fr)
ZA (1) ZA200503988B (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6670178B1 (en) 1992-07-10 2003-12-30 Transkaryotic Therapies, Inc. In Vivo production and delivery of insulinotropin for gene therapy
DE10164139A1 (de) 2001-12-27 2003-07-10 Bayer Ag 2-Heteroarylcarbonsäureamide
EP1603585A2 (fr) 2003-03-14 2005-12-14 Bristol-Myers Squibb Company Polynucleotide codant un nouveau variant de recepteur de hm74, hgprbmy74 couple a une proteine g humaine
US8383657B2 (en) 2007-12-21 2013-02-26 Abbott Laboratories Thiazolylidine urea and amide derivatives and methods of use thereof
EP2633868A1 (fr) * 2008-02-13 2013-09-04 Targacept, Inc. Combinaison d'agonistes nicotiniques alpha 7 et d'antipsychotiques
TW201031664A (en) 2009-01-26 2010-09-01 Targacept Inc Preparation and therapeutic applications of (2S,3R)-N-2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)-3,5-difluorobenzamide
KR20180101641A (ko) 2010-05-17 2018-09-12 포럼 파마슈티칼즈 인크. (R)-7-클로로-N-(퀴누클리딘-3-일)벤조[b]티오펜-2-카르복사미드 히드로클로리드 모노히드레이트의 결정질 형태
EP3461481A1 (fr) 2012-05-08 2019-04-03 Forum Pharmaceuticals Inc. Procédés de maintien, de traitement ou d'amélioration de la fonction cognitive

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1988002751A1 (fr) * 1986-10-13 1988-04-21 Asahi Kasei Kogyo Kabushiki Kaisha Derives de pyridine
AR036040A1 (es) * 2001-06-12 2004-08-04 Upjohn Co Compuestos de heteroarilo multiciclicos sustituidos con quinuclidinas y composiciones farmaceuticas que los contienen

Also Published As

Publication number Publication date
CA2506529A1 (fr) 2004-06-24
US20050165047A1 (en) 2005-07-28
EP1572700A1 (fr) 2005-09-14
KR20050087826A (ko) 2005-08-31
EA200500738A1 (ru) 2005-12-29
WO2004052894A1 (fr) 2004-06-24
HRP20050494A2 (en) 2005-10-31
TW200427691A (en) 2004-12-16
AU2003302911A1 (en) 2004-06-30
MXPA05005943A (es) 2005-08-18
AR042295A1 (es) 2005-06-15
CN1720248A (zh) 2006-01-11
OA12968A (en) 2006-10-13
BR0317019A (pt) 2005-10-25
JP2006510664A (ja) 2006-03-30
CR7859A (es) 2005-07-08
IS7844A (is) 2005-05-12
ECSP055834A (es) 2005-08-11
NO20052560L (no) 2005-08-17
NO20052560D0 (no) 2005-05-26
ZA200503988B (en) 2006-09-27
PL377052A1 (pl) 2006-01-23

Similar Documents

Publication Publication Date Title
MA65277B1 (fr) Inhibiteurs de l'inflammasome nlrp3
MA27883A1 (fr) Derives de pyrido [2,1-a] isoquinoline utilises comme inhibiteurs de dpp-iv
MA27957A1 (fr) Agents derivatifs de quinolinone comme inhibiteurs de tyrosine kinase
TNSN99073A1 (fr) Pyrazolopyrimidinones nouvelles, procede pour leur preparation et compositions pharmaceutiques les contenant
TNSN01077A1 (fr) Derives de tropane nouveaux, procede pour leur preparation et compositions les contenant
TNSN00198A1 (fr) COMPOSES NOUVEAUX INHIBITEURS DE cGMP PDE, PROCEDE POUR LEUR PREPARATION ET FORMULATIONS LES CONTENANT.
TNSN98053A1 (fr) Pyrazolopyrimidinones nouvelles, procede pour leur preparation et compositions les contenant.
MA24694A1 (fr) Derives de thienopyrimidine et thienopyridine utiles comme agents anticancereux, et compositions les contenant.
TNSN04151A1 (fr) Derives de nicotinamide utiles comme inhibiteurs de pde4
TNSN04137A1 (fr) Nouveaux composes heterocycliques, actifs comme inhibiteurs de beta-lactamases
DE602004007239D1 (de) 4-AMINOTHIENOÄ2,3-dÜ PYRIMIDIN -6-CARBONITRIL-DERIVATIVE ZUR VERWENDUNG ALS PDE7 INHIBITOREN
TN2009000138A1 (fr) Biaryl-ether-urees
LU90053I2 (fr) Topotecan et ses sels et dérivés pharmaceutiquement acceptables (Hycamtin)
HUP0401538A2 (hu) Új, helyettesített aminometilcsoportot tartalmazó N-(arilszulfonil)-béta-aminosav-származékok, előállításukra alkalmas eljárás és a vegyületeket tartalmazó gyógyászati készítmények
MA27604A1 (fr) Sels fumarates cristallins de furo [2,3-c] pyridinylcarboxamide a substituant 1- azabicyclo [2.2.2] octyle, compositions les contenant, et leur preparation
TNSN01009A1 (fr) (+) - 6 - [amino - (6 - chloro - pyridine - 3 - yl) - (3 - methyl - 3h - imidazole - 4 - yl) - methyl ] - 4 - ( 3 - chloro-phenyl) -1- cyclopropylmethyl - 1h - quinoleine - 2 - one, procede pour sa preparation et composition la contenant
AU2003284632A1 (en) Isoquinoline compounds and medicinal use thereof
TW200502221A (en) Novel lactams and uses thereof
KR100234863B1 (ko) 사람 면역결핍 바이러스 프로테아제 억제제
MA30756B1 (fr) Derives de cinnamoyl-piperazine et leur utilisation comme antagonistes par-1
MA27436A1 (fr) Derives de pyridine inhibiteurs de la cox-2
CA2793138C (fr) Sels d'hydroxybenzoate de composes de metanicotine
EP0727994A4 (fr) Procedes et compositions antipyretiques et analgesiques contenant de l'acide etodolique r optiquement pur
TNSN96083A1 (fr) 5, 6-DIHYDRO-9H-PYRAZOLO (3,4-C) -1, 2, 4-TRIAZOLO ( 4,3-α ) PYRIDINES TRICYCLIQUES, PROCEDE POUR LEUR PREPARATION ET COMPOSITIONS LES CONTENANT
TNSN01094A1 (fr) Derives de 3-azabicyclo [3,1,0] hexane nouveaux, procede pour leur preparation et compositions les contenant